Literature DB >> 17708619

Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodol-targetting intervention radiology.

Kazutaka Kurokohchi1, Akihiro Deguchi, Tsutomu Masaki, Takashi Himoto, Hirohito Yoneyama, Mitsuyoshi Kobayashi, Tsuyoshi Maeta, Takaaki Kiuchi, Fumikazu Kohi, Hisaaki Miyoshi, Tomohiko Taminato, Shigeki Kuriyama.   

Abstract

We report a case of hypovascular advanced hepa-tocellular carcinoma (HCC) successfully treated with a novel combination therapy of percutaneous ethanol-lipiodol injection (PELI) and intervention radiology (IVR), lipiodol-targetting IVR (Lipi-IVR). The present case had a hypovascular HCC (3 cm in diameter) located in the S6 region of the liver. Although the tumor was not detectable at all by both of early and late phase of helical dynamic computed tomography (CT), it could be detected by ultrasonography (US) as a low echoic space occupying lesion (SOL) beside the gallbladder and right kidney. Serum levels of alpha fetoprotein (AFP) and AFP-L3 were extremely high. Combination therapy of PELI, firstly reported in our department, and IVR (PELI and IVR, lipiodol-targetting IVR) was performed twice for the treatment. PELI could effectively visualize the location of the tumor for IVR treatment and show the presence of a thin blood vessel branching from the right hepatic artery flowing into the lipiodol deposit. After treatment, the serum levels of AFP and AFP-L3 were rapidly decreased to normal and maintained for more than eight months. Thus, this case expressing the tremendous effect might give us insight into the effectiveness of the novel combination therapy of PELI and IVR for the treatment of hypovascular HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17708619      PMCID: PMC4250872          DOI: 10.3748/wjg.v13.i32.4398

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply.

Authors:  S Rossi; F Garbagnati; R Lencioni; H P Allgaier; A Marchianò; F Fornari; P Quaretti; G D Tolla; C Ambrosi; V Mazzaferro; H E Blum; C Bartolozzi
Journal:  Radiology       Date:  2000-10       Impact factor: 11.105

2.  Thoracoscopic ethanol injection and radiofrequency ablation for the treatment of hepatocellular carcinoma located immediately under the diaphragm.

Authors:  Kazutaka Kurokohchi; Shunichi Hirai; Tomohiro Ohgi; Masahiro Ono; Akira Yoshitake; Kazuo Ebara; Yasuhiro Kitamura; Yoshitaka Kasai; Tsuyoshi Maeta; Takaaki Kiuchi; Tsutomu Masaki; Hirohito Yoneyama; Fumikazu Kohi; Shigeki Kuriyama
Journal:  Int J Oncol       Date:  2006-08       Impact factor: 5.650

Review 3.  New aspects of diagnosis and therapy of hepatocellular carcinoma.

Authors:  J Bruix; A J Hessheimer; A Forner; L Boix; R Vilana; J M Llovet
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

4.  Successful treatment of large-size advanced hepatocellular carcinoma by transarterial chemoembolization followed by the combination therapy of percutaneous ethanol-lipiodol injection and radiofrequency ablation.

Authors:  Kazutaka Kurokohchi; Naoki Hosomi; Akira Yoshitake; Tomohiro Ohgi; Masahiro Ono; Tsuyoshi Maeta; Takaaki Kiuchi; Ichiro Matsumoto; Tsutomu Masaki; Hirohito Yoneyama; Fumikazu Kohi; Shigeki Kuriyama
Journal:  Oncol Rep       Date:  2006-11       Impact factor: 3.906

5.  Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma.

Authors:  Kazutaka Kurokohchi; Seishiro Watanabe; Tsutomu Masaki; Naoki Hosomi; Yoshiaki Miyauchi; Takashi Himoto; Yasuhiko Kimura; Seiji Nakai; Akihiro Deguchi; Hirohito Yoneyama; Shuhei Yoshida; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

6.  Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

Authors:  S A Curley; F Izzo; L M Ellis; J Nicolas Vauthey; P Vallone
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

7.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

Review 8.  Hepatocellular carcinoma.

Authors:  K Okuda
Journal:  J Hepatol       Date:  2000       Impact factor: 25.083

9.  Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation.

Authors:  S N Goldberg; G S Gazelle; C C Compton; P R Mueller; K K Tanabe
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

10.  Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat.

Authors:  Kazutataka Kurokohchi; Seishiro Watanabe; Tsutomu Masaki; Naoki Hosomi; Toshiharu Funaki; Keiji Arima; Shuhei Yoshida; Seiji Nakai; Masayuki Murota; Yoshiaki Miyauchi; Shigeki Kuriyama
Journal:  Int J Oncol       Date:  2002-09       Impact factor: 5.650

View more
  3 in total

1.  Computed tomography fluoroscopy-guided radiofrequency ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas invisible on ultrasonographic images.

Authors:  Haruyuki Takaki; Koichiro Yamakado; Atsuhiro Nakatsuka; Tomomi Yamada; Junji Uraki; Masataka Kashima; Takashi Yamanaka; Katsuya Shiraki; Yoshiyuki Takei; Kan Takeda
Journal:  Int J Clin Oncol       Date:  2011-10-22       Impact factor: 3.402

2.  Bifunctional staining for ex vivo determination of area at risk in rabbits with reperfused myocardial infarction.

Authors:  Yuanbo Feng; Zhan-Long Ma; Feng Chen; Jie Yu; Marlein Miranda Cona; Yi Xie; Yue Li; Yicheng Ni
Journal:  World J Methodol       Date:  2013-09-26

3.  Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.

Authors:  Chiara Briani; Marco Di Pietropaolo; Massimo Marignani; Francesco Carbonetti; Paola Begini; Vincenzo David; Elsa Iannicelli
Journal:  J Gastrointest Cancer       Date:  2018-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.